Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026. Dr. Tsai will bring more than ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

Jacob Elordi as James Bond? Chop half a foot off him, then we’ll talk. The 28-year-old Australian star of Euphoria, Saltburn, Frankenstein and the current box-office smash Wuthering Heights is ...

"Stroking her soft face and trying to keep the tears back, I knew our lives would never be the same." ...

The free event will take place between 10am and 3pm, with the British Heart Foundation encouraging shoppers to take part.

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...

New modular robot design leverages shared electronics and power to maintain function even when modules fail.

SEPTA Senior ID Event: will be Wednesday, Feb. 18 from 11 a.m. to 1 p.m. at Surrey Services for Seniors, 505 Parkway in Broomall. Anyone 65 and older can complete an application for a free SEPTA ...